Recommended Topic Related To:

Follistim AQ Cartridge

"Nov. 19, 2012 -- This week or next, 2012 officially will become America's worst year ever for death and brain damage from West Nile virus.

More than 2,600 Americans already suffer paralysis or other lingering neurological damage from "...

Follistim AQ Cartridge

Follistim AQ Cartridge

Follistim AQ Cartridge Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Follistim AQ Cartridge (follitropin beta injection) contains human follicle-stimulating hormone (hFSH) and is used to treat infertility in women that is not due to primary ovarian failure. It is also used to stimulate sperm production in men. Common side effects include headache, abdominal bloating, constipation, diarrhea, nausea, pelvic pain, vaginal hemorrhage and injection site reaction.

The dosing scheme of Follistim AQ Cartridge is stepwise and is individualized for each woman. Follistim AQ Cartridge may interact with other drugs. Tell your doctor all medications and supplements you use. Follistim AQ Cartridge should not be used during pregnancy. It is unknown if this drug is excreted in human milk. Consult your doctor before breastfeeding.

Our Follistim AQ Cartridge (follitropin beta injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Follistim AQ Cartridge FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The following serious adverse reactions are discussed elsewhere in the labeling:

Clinical Study Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

Ovulation Induction

In a single cycle, multi-center, assessor-blind, parallel group, comparative study, a total of 172 chronic anovulatory women who had failed to ovulate and/or conceive with clomiphene citrate therapy, were randomized and treated with Follistim (105) or a urofollitropin comparator. Adverse reactions with an incidence of greater than 2% in either treatment group are listed in Table 2.

Table 2: Common Adverse Reactions Reported at a Frequency of ≥ 2% in an Assessor-Blind, Comparative Study of Anovulatory Women Receiving Ovulation Induction

System Organ Class/
Adverse Reactions
Treatment Number (%) of Women
Follistim
N=105
n (%)
Comparator
N=67
n (%)
Gastrointestinal disorders
  Abdominal discomfort 3 (2.9) 1 (1.5)
  Abdominal pain 3 (2.9) 2 (3.0)
  Abdominal pain lower 3 (2.9) 1 (1.5)
Reproductive system and breast disorders
  Ovarian cyst 3 (2.9) 2 (3.0)
  Ovarian hyperstimulation syndrome 8 (7.6) 3 (4.5)
General disorders and administration site conditions
  Pyrexia 0 (0.0) 2 (3.0)

Adverse reactions reported commonly (greater than or equal to 2% of women treated with Follistim) in other ovulation induction clinical trials were headache, abdominal distension, constipation, diarrhea, nausea, pelvic pain, uterine enlargement, vaginal hemorrhage and injection site reaction.

In Vitro Fertilization/Intracytoplasmic Sperm Injection

In a single cycle, multi-center, double-blind, parallel group, comparative study, a total of 1509 women were randomized to receive controlled ovarian stimulation with either Follistim AQ Cartridge (751 women were treated with Follistim AQ Cartridge) or a comparator and pituitary suppression with a gonadotropin releasing hormone (GnRH) antagonist as part of an in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle. Table 3 lists adverse reactions with an incidence of greater than 2% in the group of women treated with Follistim AQ Cartridge.

Table 3: Common Adverse Reactions Reported At a Frequency of ≥ 2% in a Randomized, Double-blind, Active-controlled, Comparative Study of Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization or Intracytoplasmic Sperm Injection Cycle

System Organ Class/
Adverse Reactions
Follistim AQ Cartridge Treatment
N = 751
na (%)
Nervous System disorders
  Headache 55 (7.3%)
Gastrointestinal disorders
  Nausea 29 (3.9%)
Reproductive system and breast disorders
  Ovarian Hyperstimulation Syndrome 48 (6.4%)
  Pelvic discomfort 62 (8.3%)
  Pelvic Pain 41 (5.5%)
General disorders and Administration site conditions
  Fatigue 17 (2.3%)
a n = number of women with the adverse reaction

Induction of Spermatogenesis

In an open-label, non-comparative clinical trial, 49 men with hypogonadotropic hypogonadism were enrolled to received pretreatment with hCG, followed by combination therapy with hCG and Follistim for induction of spermatogenesis. Of the 49 men, 30 received weekly Follistim doses of 450 international units; 24 of these 30 men received a total of 48 weeks of treatment with Follistim. Adverse reactions occurring with an incidence of greater than 2% in the 30 men treated with Follistim are listed in Table 4.

Table 4: Common Adverse Reactions Reported At a Frequency of ≥ 2% in an Open-Label Clinical Trial in Men with Hypogonadotropic Hypogonadism

System Organ Class/
Adverse Reactions
Follistim Treatment
N=30
n (%)
Nervous system disorders
  Headache 2 (6.7)
General disorders and administration site disorders
  Injection site reaction 2 (6.7)
  Injection site pain 2 (6.7)
Skin and cutaneous tissue disorders
  Acne 2 (6.7)
  Rash 1 (3.3)
Reproductive system and breast disorders
  Gynecomastia 1 (3.3)
Neoplasms benign, malignant and unspecified
  Dermoid cyst 1 (3.3)

Postmarketing Experience

The following adverse reactions have been identified during post approval use of Follistim and/or Follistim AQ Cartridge. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal disorders

Abdominal distension, abdominal pain, constipation, diarrhea

General disorders and administration site conditions

Injection site reaction

Reproductive system and breast disorders

Breast tenderness, metrorrhagia, ovarian enlargement, vaginal hemorrhage

Skin and subcutaneous tissue disorders

Rash

Vascular disorders

Thromboembolism [see WARNINGS AND PRECAUTIONS]

Read the entire FDA prescribing information for Follistim AQ Cartridge (Follitropin Beta Injection) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Trying to Conceive

Get tips and advances in treatment.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations